Asparlas market seen growing to $1.91 million by 2030

The Business Research Company says the global market for Asparlas (calaspargase pegol) is rising on demand for targeted leukemia therapies and longer-acting formulations. The report projects the market will grow from $1.26 million in 2025 to $1.91 million by 2030, with North America leading and Asia-Pacific set for the fastest expansion.

Why it matters: - The Asparlas market is tied to treatment for acute lymphoblastic leukemia, a blood and bone marrow cancer. - Demand for longer-lasting and less immunogenic leukemia therapies is supporting adoption of calaspargase pegol. - The market forecast points to continued growth in pediatric oncology and targeted cancer care.

What happened: - The Business Research Company released its Asparlas (calaspargase pegol) Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report values the market at $1.26 million in 2025 and $1.37 million in 2026. - The report projects the market will reach $1.91 million by 2030, implying an 8.6% CAGR from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Asparlas is an enzyme therapy used to treat certain types of acute lymphoblastic leukemia. - The drug works by breaking down asparagine, an amino acid leukemia cells need to grow and survive. - The therapy converts asparagine into aspartic acid and ammonia. - Leukemia cells cannot produce enough asparagine on their own, which limits their proliferation when the therapy removes it. - Historical market growth reflects clinical success for asparaginase treatments, rising pediatric leukemia incidence, limits of native asparaginase, improved survival rates and regulatory approvals for pegylated enzyme formulations. - Future growth is expected to come from pediatric oncology programs, rising global ALL diagnosis rates, demand for longer-acting formulations, more oncology-specialized hospitals and improvements in enzyme stabilization technologies. - The report cites rising ALL incidence as a major demand driver. - The American Cancer Society projected new leukemia cases in the United States would rise from 59,610 in 2023 to about 62,770 in 2024. - Personalized medicine is another driver for the market. - The Personalized Medicine Coalition reported the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Higher healthcare expenditure is also supporting demand. - The Office for National Statistics reported UK healthcare expenditure rose 5.6% from 2022 to 2023, compared with 0.9% growth the year before.

Between the lines: - The report suggests Asparlas is benefiting from a broader shift toward precision oncology and therapies designed for longer dosing intervals. - The market remains small in dollar terms, which means even modest absolute gains translate into meaningful percentage growth. - Regional leadership in North America and faster growth in Asia-Pacific point to a mature core market and a developing expansion market.

What's next: - The report expects continued gains through 2030 as ALL diagnosis rates rise and healthcare systems expand access to advanced oncology treatments. - The Business Research Company said the 2026 edition of its market reports includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The company also provided contact details for its expert and listed LinkedIn, Facebook and X social channels.